Chink in Alzheimer's armour? drug slows cognitive decline, but could have side effects
India, Nov. 30 -- Latest data raises apprehensions about the occurrence of brain enlargement and bleeding in patients
Scientists lauded the start of a new era of therapies for Alzheimer's Disease after a drug was proven to slow cognitive decline in patients in the early phases of the disease.
Some experts are hopeful that the discovery, which comes after decades of futile attempts, would eventually open the door for treatments that could finally lead to a cure.
The findings of the clinical trials were published in the New England Journal of Medicine November 29, 2022.
The developers of the drug, Lecanemab - US-based Biogen and the Japanese drug maker Eisai - released the preliminary findings of a clinical trial involving over 1,800 pa...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.